Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX

LPTX

NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Halper Sadeh LLC (PRNewsfoto/Halper Sadeh LLP)

Albireo Pharma, Inc. (NASDAQ: ALBO)'s sale to Ipsen. Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration's approval of Bylvay in the Biliary Atresia indication by December 31, 2027. If you are an Albireo shareholder, click here to learn more about your rights and options.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)'s sale to Sun Pharmaceutical Industries Limited. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. If you are a Concert shareholder, click here to learn more about your rights and options.

Evoqua Water Technologies Corp. (NYSE: AQUA)'s sale to Xylem Inc. for 0.480 shares of Xylem for each Evoqua share. If you are an Evoqua shareholder, click here to learn more about your rights and options.

Leap Therapeutics, Inc. (NASDAQ: LPTX)'s merger with Flame Biosciences, Inc. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders. If you are a Leap shareholder, click here to learn more about your legal rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-albo-cnce-aqua-lptx-301734717.html

SOURCE Halper Sadeh LLP